It’s back to the drawing board for the FDA.
After years of slow reaction to pharma marketing online, the agency announced this week a new research initiative to better understand how consumers process short-form posts and ads.
More precisely, the FDA is trying to determine whether links in tweets and Google ads can independently convey all the necessary information about product risk.
